Literature DB >> 21068353

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial.

Marianne E Visser1, Harleen Ms Grewal, Elizabeth C Swart, Muhammad A Dhansay, Gerhard Walzl, Sonja Swanevelder, Carl Lombard, Gary Maartens.   

Abstract

BACKGROUND: Low serum concentrations of vitamin A and zinc are common in tuberculosis and may have an adverse effect on host cell-mediated responses. The role of adjunctive micronutrient supplementation on treatment outcomes is uncertain.
OBJECTIVE: The objective was to assess the efficacy of vitamin A and zinc supplementation on sputum smear and culture conversion and time to culture detection in adults with sputum smear-positive pulmonary tuberculosis.
DESIGN: Participants attending a primary care tuberculosis clinic in Cape Town, South Africa, were randomly assigned to receive micronutrients (single dose of 200,000 IU retinyl palmitate plus 15 mg Zn/d for 8 wk) or matching placebo. Sputum was collected weekly for 8 wk for auramine staining and culture on liquid media (BACTEC MGIT 960; Becton Dickinson, Sparks, MD). Performance status, chest radiographs, and anthropometric measures were assessed at baseline and again at 8 wk.
RESULTS: The participants (n = 154) were randomly assigned to the micronutrient (n = 77) or placebo (n = 77) group. Twenty participants were HIV infected (13%), and 12 participants had an unknown HIV status (8%). No differences in time to smear or culture conversion were observed between the treatment groups by Kaplan-Meier analysis (P = 0.15 and P = 0.38, respectively; log-rank test). Log-logistic regression analysis found no significant group interaction effect in time to culture detection over the 8-wk period (P = 0.32). No significant differences in weight gain (2.3 ± 3.5 compared with 2.2 ± 2.4 kg, P = 0.68) or radiologic resolution were observed between the treatment groups.
CONCLUSION: Supplementation with vitamin A and zinc did not affect treatment outcomes in participants with pulmonary tuberculosis at 8 wk. This trial was registered at controlled-trials.com as ISRCTN80852505.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068353     DOI: 10.3945/ajcn.110.001784

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  26 in total

1.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 2.  Nutritional supplements for people being treated for active tuberculosis.

Authors:  Liesl Grobler; Sukrti Nagpal; Thambu D Sudarsanam; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2016-06-29

3.  All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2.

Authors:  Matthew Wheelwright; Elliot W Kim; Megan S Inkeles; Avelino De Leon; Matteo Pellegrini; Stephan R Krutzik; Philip T Liu
Journal:  J Immunol       Date:  2014-02-05       Impact factor: 5.422

4.  Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Authors:  Emmanuel Chigutsa; Jotam G Pasipanodya; Marianne E Visser; Paul D van Helden; Peter J Smith; Frederick A Sirgel; Tawanda Gumbo; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

5.  The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Authors:  Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Shashikant Srivastava; Devyani Deshpande; Marianne E Visser; Emmanuel Chigutsa; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

7.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

8.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

Review 9.  Impact of Childhood Malnutrition on Host Defense and Infection.

Authors:  Marwa K Ibrahim; Mara Zambruni; Christopher L Melby; Peter C Melby
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

10.  A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.

Authors:  Emmanuel Chigutsa; Kashyap Patel; Paolo Denti; Marianne Visser; Gary Maartens; Carl M J Kirkpatrick; Helen McIlleron; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.